A novel ErbB2 epitope targeted by human antitumor immunoagents

FEBS Journal

Volumn 278, Issue 7, 2011, Pages 1156-1166

  Troise, Fulvia ^a,b   Monti, Maria ^a,b   Merlino, Antonello ^a,c   Cozzolino, Flora ^a,b   Fedele, Carmine ^a   Russo Krauss, Irene ^a,c   Sica, Filomena ^a,c   Pucci, Piero ^a,b   D'Alessio, Giuseppe ^a   De Lorenzo, Claudia ^a,b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c CNR   (Italy)

Author keywords

breast cancer; cardiotoxicity; ErbB2 Her2; Herceptin trastuzumab; immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 HUMAN COMPACT ANTIBODY; EPITOPE; ERBICIN; ERBICIN RIBONUCLEASE FUSION PROTEIN; PERTUZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; BINDING ASSAY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EXTRACELLULAR SPACE; HUMAN; MASS SPECTROMETRY; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 79952857785     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2011.08041.x     Document Type: Article

References (34)

1. Baselga J, &, Albanell J, (2001) Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 12 (Suppl 1), S35-S41. (Pubitemid 32750583)
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, &, McGuire WL, (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182. (Pubitemid 17231334)
3. Stebbing J, Copson E, &, O'Reilly S, (2000) Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat Rev 26, 287-290. (Pubitemid 30604039)
4. Sparano JA, (2001) Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol 28, 20-27.
5. Cardoso F, Piccart MJ, Durbecq V, &, Di Leo A, (2002) Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin Breast Cancer 3, 247-257. discussion 258-249. (Pubitemid 35423144)
6. De Lorenzo C, &, D'Alessio G, (2008) From immunotoxins to immunoRNases. Curr Pharm Biotechnol 9, 210-214. (Pubitemid 352024697)
7. De Lorenzo C, Palmer DB, Piccoli R, Ritter MA, &, D'Alessio G, (2002) A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res 8, 1710-1719. (Pubitemid 34633726)
8. De Lorenzo C, Arciello A, Cozzolino R, Palmer DB, Laccetti P, Piccoli R, &, D'Alessio G, (2004) A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res 64, 4870-4874. (Pubitemid 38924531)
9. De Lorenzo C, Tedesco A, Terrazzano G, Cozzolino R, Laccetti P, Piccoli R, &, D'Alessio G, (2004) A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. Br J Cancer 91, 1200-1204. (Pubitemid 39336263)
10. De Lorenzo C, Cozzolino R, Carpentieri A, Pucci P, Laccetti P, &, D'Alessio G, (2005) Biological properties of a human compact anti-ErbB2 antibody. Carcinogenesis 26, 1890-1895. (Pubitemid 41631261)
11. De Lorenzo C, Troise F, Cafaro V, &, D'Alessio G, (2007) Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin. Br J Cancer 97, 1354-1360. (Pubitemid 350114782)
12. Riccio G, Esposito G, Leoncini E, Contu R, Condorelli G, Chiariello M, Laccetti P, Hrelia S, D'Alessio G, &, De Lorenzo C, (2009) Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J 23, 3171-3178.
13. Gelardi T, Damiano V, Rosa R, Bianco R, Cozzolino R, Tortora G, Laccetti P, D'Alessio G, &, De Lorenzo C, (2010) Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours. Br J Cancer 102, 513-519.
14. Badache A, &, Hynes NE, (2004) A new therapeutic antibody masks ErbB2 to its partners. Cancer Cell 5, 299-301.
15. Cho HS, &, Leahy DJ, (2002) Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297, 1330-1333. (Pubitemid 34913167)
16. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, &, Leahy DJ, (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756-760. (Pubitemid 36227628)
17. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, &, Sliwkowski MX, (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5, 317-328. (Pubitemid 38482068)
18. Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, &, Sela M, (1991) Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA 88, 8691-8695. (Pubitemid 21915423)
19. Yip YL, Novotny J, Edwards M, &, Ward RL, (2003) Structural analysis of the ErbB-2 receptor using monoclonal antibodies: implications for receptor signalling. Int J Cancer 104, 303-309. (Pubitemid 36249812)
20. Troise F, Cafaro V, Giancola C, D'Alessio G, &, De Lorenzo C, (2008) Differential binding of human immunoagents and Herceptin to the ErbB2 receptor. FEBS J 275, 4967-4979.
21. Al-Lazikani B, Lesk AM, &, Chothia C, (1997) Standard conformations for the canonical structures of immunoglobulins. J Mol Biol 273, 927-948. (Pubitemid 27493729)
22. Chothia C, &, Lesk AM, (1987) Canonical structures for the hypervariable regions of immunoglobulins. J Mol Biol 196, 901-917. (Pubitemid 17127946)
23. Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR, et al. (1989) Conformations of immunoglobulin hypervariable regions. Nature 342, 877-883. (Pubitemid 20021331)
24. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, &, Sela M, (2009) Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci USA 106, 3294-3299.
25. Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, &, Yarden Y, (2005) Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci USA 102, 1915-1920. (Pubitemid 40261987)
26. Ay J, Keitel T, Kuttner G, Wessner H, Scholz C, Hahn M, &, Hohne W, (2000) Crystal structure of a phage library-derived single-chain Fv fragment complexed with turkey egg-white lysozyme at 2.0 A resolution. J Mol Biol 301, 239-246.
27. Laskowski RA, Moss DS, &, Thornton JM, (1993) Main-chain bond lengths and bond angles in protein structures. J Mol Biol 231, 1049-1067. (Pubitemid 23209879)
28. Sippl MJ, (1993) Recognition of errors in three-dimensional structures of proteins. Proteins 17, 355-362. (Pubitemid 23358545)
29. Collaborative Computational Project no. 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr 50, 760-763.
30. van Dijk AD, Boelens R, &, Bonvin AM, (2005) Data-driven docking for the study of biomolecular complexes. FEBS J 272, 293-312.
31. Gabb HA, Jackson RM, &, Sternberg MJ, (1997) Modelling protein docking using shape complementarity, electrostatics and biochemical information. J Mol Biol 272, 106-120. (Pubitemid 27395541)
32. Reynolds C, Damerell D, &, Jones S, (2009) ProtorP: a protein-protein interaction analysis server. Bioinformatics 25, 413-414.
33. McDonald IK, &, Thornton JM, (1994) Satisfying hydrogen bonding potential in proteins. J Mol Biol 238, 777-793. (Pubitemid 24168633)
34. Lawrence MC, &, Colman PM, (1993) Shape complementarity at protein/protein interfaces. J Mol Biol 234, 946-950. (Pubitemid 24027225)